A SEROEPIDEMIOLOGIC STUDY OF CHLAMYDIA-PNEUMONIAE IN RHODE-ISLAND - EVIDENCE OF SEROLOGIC CROSS-REACTIVITY

Objective: Although Chlamydia pneumoniae is considered a common cause of pneumonia worldwide, the evidence is mainly serologic. Therefore, w e examined whether the currently used chlamydial microimmunofluorescen ce (MIF) antibody test is specific for C pneumoniae infection. Design and setting: Secondary analysis of data from a cohort study of sarcoid osis among the graduates of ten consecutive apprenticeship classes of firefighters and police officers. Participants: One hundred forty-seve n young adult men. Measurements: Immunoglobulin G and M antibodies to C pneumoniae, 15 serovars of C trachomatis, and 2 strains of C psittac i as measured by MIF. Results: Evidence of previous C pneumoniae and C trachomatis infection (IgG greater-than-or-equal-to 1:16 vet <1:512) was present in 108 (73 percent) and 59 (40 percent) subjects, respecti vely. Serologic evidence of recent C pneumoniae and C trachomatis infe ction (IgM greater-than-or-equal-to 1:16 or IgG greater-than-or-equal- to 1:512) was present in 19 (13 percent) and 14 (10 percent) subjects, respectively. Chlamydia pneumoniae and C trachomatis IgM titers were highly correlated (r=0.80; 95 percent CI, 0.73 to 0.85) while C pneumo niae and C trachomatis IgG titers were fairly correlated (r=0.44; 95 p ercent CI, 0.30 to 0.56). Conclusions: The C pneumoniae seroprevalence of 86 percent is the highest yet reported. The correlations between C pneumoniae and C trachomatis antibody titers suggest that chlamydial MIF may be less specific than is generally appreciated. Moreover, the observed 13 percent seroprevalence of recent C pneumoniae infection in a healthy working population challenges the serologically based belie f that this agent accounts for 6 to 10 percent of community-acquired p neumonia. A more objective, more specific test is needed in the serodi agnosis of C pneumoniae infection.